Cargando…
Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report
BACKGROUND: Checkpoint-Inhibition has revolutionized the treatment for several entities such as melanoma and renal cell carcinoma. The first encouraging experience in ovarian cancer was reported for nivolumab, a fully humanized anti-programmed death-1 antibody. Pseudoprogression is a new phenomenon...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682498/ https://www.ncbi.nlm.nih.gov/pubmed/31396474 http://dx.doi.org/10.5306/wjco.v10.i7.247 |